{"id":"tiva-neostigmine-50","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased salivation"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle fasciculations"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":{"chemblId":"CHEMBL278020","moleculeType":"Small molecule","molecularWeight":"223.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neostigmine is a reversible cholinesterase inhibitor that prevents the breakdown of acetylcholine by acetylcholinesterase. This leads to accumulation of acetylcholine in the synaptic cleft, prolonging and enhancing neuromuscular transmission. It is used to reverse neuromuscular blockade and treat myasthenia gravis by improving muscle strength through increased acetylcholine availability.","oneSentence":"Neostigmine inhibits acetylcholinesterase, increasing acetylcholine levels at the neuromuscular junction to enhance muscle contraction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:55.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of neuromuscular blockade"},{"name":"Myasthenia gravis"},{"name":"Postoperative ileus"}]},"trialDetails":[{"nctId":"NCT04002271","phase":"PHASE4","title":"Total Knee Replacement TIVA With Robotic Arm Assisted","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-07-22","conditions":"Postoperative Pain","enrollment":180},{"nctId":"NCT05037006","phase":"PHASE4","title":"Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade","status":"UNKNOWN","sponsor":"Pontificia Universidade Catolica de Sao Paulo","startDate":"2021-10-01","conditions":"Neuromuscular Blockade, Neuromuscular Blockade, Residual","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TIVA"],"phase":"marketed","status":"active","brandName":"TIVA - Neostigmine 50","genericName":"TIVA - Neostigmine 50","companyName":"Pontificia Universidade Catolica de Sao Paulo","companyId":"pontificia-universidade-catolica-de-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neostigmine inhibits acetylcholinesterase, increasing acetylcholine levels at the neuromuscular junction to enhance muscle contraction. Used for Reversal of neuromuscular blockade, Myasthenia gravis, Postoperative ileus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}